Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nenocorilant · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1a: Nenocorilant 200 mg and Nivolumab | EXPERIMENTAL | Cohort 1a: Patients will receive nenocorilant 200 mg orally under fed conditions once daily, and nivolumab 240 mg IV every 2 weeks. After 3 months of treatment, patients may choose to switch the nivolumab regimen to 480 mg IV every 4 weeks if the nenocorilant nivolumab combination is tolerated. |
| Cohort 1b: Nenocorilant 300 mg and Nivolumab | EXPERIMENTAL | Cohort 1b: Patients will receive nenocorilant 300 mg orally under fed conditions once daily, and nivolumab 240 mg IV every 2 weeks. After 3 months of treatment, patients may choose to switch the nivolumab regimen to 480 mg IV every 4 weeks if the nenocorilant nivolumab combination is tolerated. |
| Cohort 1c: Nenocorilant 400 mg and Nivolumab | EXPERIMENTAL | Cohort 1c: Patients will receive nenocorilant 400 mg orally under fed conditions once daily, and nivolumab 240 mg IV every 2 weeks. After 3 months of treatment, patients may choose to switch the nivolumab regimen to 480 mg IV every 4 weeks if the nenocorilant nivolumab combination is tolerated. |
| Name | Type | Description |
|---|---|---|
| Nenocorilant 200 mg | DRUG | Nenocorilant 200 mg will be supplied as 50 and/or 100 mg tablets. |
| Nenocorilant 300 mg | DRUG | Nenocorilant 300 mg will be supplied as 50 and/or 100 mg tablets. |
| Nenocorilant 400 mg | DRUG | Nenocorilant 400 mg will be supplied as 50 and/or 100 mg tablets. |
| Nivolumab | DRUG | Nivolumab 240 mg and 480 mg will be supplied as single-dose 120 mg/12 mL (10 mg/mL) vials. |
Inclusion Criteria: Part 1 * Signed and dated institutional review board (IRB)/ independent ethics committee (IEC)-approved informed consent form (ICF) * Has solid malignancies that have received all available standard therapies for the specific tumor type or for which no standard therapy exists, ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
Nenocorilant is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is currently in Phase 1 clinical development for oncology indications, specifically in patients with advanced solid malignancies.
Nenocorilant is being developed by Corcept Therapeutics Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol CORT. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with advanced solid tumors.
Nenocorilant is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to assess its safety, tolerability, and potential efficacy in treating advanced solid malignancies.
Nenocorilant is being evaluated in a Phase 1 clinical trial with the identifier NCT07276373. This two-part study combines Nenocorilant with nivolumab in patients with advanced solid malignancies. The trial is currently recruiting participants in the United States and aims to enroll approximately 50 patients aged 18 years and older.
Yes, Nenocorilant 200 mg refers to the same drug, Nenocorilant. The 200 mg designation indicates a specific dosage strength being studied in clinical trials. The investigational drug is being evaluated in combination with nivolumab for the treatment of advanced solid malignancies.